Edwards Tangible Asset Value vs Working Capital Analysis
EW Stock | USD 86.72 0.70 0.80% |
Edwards Lifesciences financial indicator trend analysis is much more than just examining Edwards Lifesciences Corp latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edwards Lifesciences Corp is a good investment. Please check the relationship between Edwards Lifesciences Tangible Asset Value and its Working Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
Tangible Asset Value vs Working Capital
Tangible Asset Value vs Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edwards Lifesciences Corp Tangible Asset Value account and Working Capital. At this time, the significance of the direction appears to have no relationship.
The correlation between Edwards Lifesciences' Tangible Asset Value and Working Capital is 0.0. Overlapping area represents the amount of variation of Tangible Asset Value that can explain the historical movement of Working Capital in the same time period over historical financial statements of Edwards Lifesciences Corp, assuming nothing else is changed. The correlation between historical values of Edwards Lifesciences' Tangible Asset Value and Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Tangible Asset Value of Edwards Lifesciences Corp are associated (or correlated) with its Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Working Capital has no effect on the direction of Tangible Asset Value i.e., Edwards Lifesciences' Tangible Asset Value and Working Capital go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Tangible Asset Value
The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.Working Capital
The difference between a company’s current assets and current liabilities, indicating the liquidity and operational efficiency of the business.Most indicators from Edwards Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. At this time, Edwards Lifesciences' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 0.36 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 169.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 4.0B | 4.3B | 4.6B | 4.9B | Total Revenue | 5.2B | 5.4B | 6.0B | 6.3B |
Edwards Lifesciences fundamental ratios Correlations
Click cells to compare fundamentals
Edwards Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edwards Lifesciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 9.8B | |
Other Current Liab | 6.4M | 39.3M | 3.9M | 311M | 15.2M | 14.4M | |
Total Current Liabilities | 902.4M | 893.9M | 1.0B | 1.0B | 1.2B | 1.3B | |
Total Stockholder Equity | 4.1B | 4.6B | 5.8B | 5.8B | 6.7B | 7.0B | |
Property Plant And Equipment Net | 1.1B | 1.5B | 1.6B | 1.7B | 1.8B | 1.9B | |
Retained Earnings | 3.7B | 4.6B | 6.1B | 7.6B | 9.0B | 9.4B | |
Non Current Assets Total | 3.5B | 4.1B | 5.3B | 5.2B | 5.3B | 5.6B | |
Non Currrent Assets Other | 101.8M | 119.6M | 110.8M | 299.1M | 463.7M | 486.9M | |
Cash And Short Term Investments | 1.5B | 1.4B | 1.5B | 1.2B | 1.6B | 1.7B | |
Net Receivables | 599.1M | 602.8M | 664.9M | 699.1M | 836.9M | 878.7M | |
Good Will | 1.2B | 1.2B | 1.2B | 1.2B | 1.3B | 688.6M | |
Common Stock Shares Outstanding | 636.6M | 631.9M | 631.2M | 624.2M | 609.4M | 550.8M | |
Liabilities And Stockholders Equity | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 9.8B | |
Non Current Liabilities Total | 1.4B | 1.8B | 1.6B | 1.5B | 1.4B | 800.7M | |
Inventory | 640.9M | 802.3M | 726.7M | 875.5M | 1.2B | 1.2B | |
Other Current Assets | 168M | 208.2M | 237.1M | 195.9M | 239.3M | 251.3M | |
Other Stockholder Equity | 344.6M | (466M) | (716.5M) | (2.2B) | (2.8B) | (2.6B) | |
Total Liab | 2.3B | 2.7B | 2.7B | 2.5B | 2.6B | 1.4B | |
Property Plant And Equipment Gross | 1.1B | 1.5B | 1.6B | 1.7B | 2.7B | 2.8B | |
Total Current Assets | 3.0B | 3.1B | 3.2B | 3.1B | 4.0B | 4.2B | |
Accumulated Other Comprehensive Income | (156M) | (161.1M) | (157.7M) | (254.9M) | (242.8M) | (230.7M) | |
Short Long Term Debt Total | 593.8M | 678.8M | 694.9M | 690.3M | 691.3M | 486.4M | |
Other Liab | 784.1M | 1.1B | 969.6M | 797.6M | 917.2M | 963.1M | |
Net Debt | (500.3M) | (488.3M) | (172.5M) | (77.7M) | (449.1M) | (426.6M) | |
Accounts Payable | 180.4M | 196.5M | 204.5M | 201.9M | 201.4M | 139.5M | |
Cash | 1.2B | 1.2B | 862.8M | 769M | 1.1B | 1.2B | |
Other Assets | 274M | 1.2B | 357.5M | 783.1M | 900.6M | 945.6M | |
Long Term Debt | 594.4M | 595M | 595.7M | 596.3M | 597M | 425.6M | |
Common Stock Total Equity | 218.1M | 636.4M | 642M | 646.3M | 743.2M | 780.4M | |
Short Term Debt | 598M | 0.0 | 25.5M | 27.2M | 24.9M | 23.7M | |
Intangible Assets | 336.5M | 331.4M | 323.6M | 285.2M | 428.4M | 449.8M | |
Common Stock | 218.1M | 636.4M | 642M | 646.3M | 650.5M | 683.0M | |
Property Plant Equipment | 1.1B | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B | |
Treasury Stock | (1.0B) | (1.3B) | (1.9B) | (2.4B) | (2.2B) | (2.1B) | |
Short Term Investments | 337.8M | 219.4M | 604M | 446.3M | 500.5M | 382.6M | |
Net Tangible Assets | 2.9B | 3.4B | 4.3B | 4.4B | 5.0B | 5.3B | |
Retained Earnings Total Equity | 3.7B | 4.6B | 6.1B | 7.6B | 8.7B | 9.2B | |
Capital Surpluse | 1.6B | 1.4B | 1.7B | 2.0B | 2.3B | 1.2B | |
Long Term Investments | 585.5M | 801.6M | 1.8B | 1.2B | 583.9M | 582.2M |
Pair Trading with Edwards Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.036 | Earnings Share 2.32 | Revenue Per Share 10.151 | Quarterly Revenue Growth 0.095 | Return On Assets 0.1205 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.